中国生物工程杂志

Engineered targeting fusion protein XE-TNFαm2 was prepared.In which,XE is the second excellular domain of CXCR4,a co-receptor of HIV/SIV. TNFαm2 is a mutation protein of TNFα.Its side effect was reduced 18 fold.It has been used in clinic for cancer therapy.In this study, Jurkat H2/9855, a standard cell line was donated toward by AIDS Reagent Program, NIH ,USA.In which, a deleted HIV mutant was inserted into chromosome of Jurkat cells to be 5’LTR-Tat-GFP-3’LTR. XE-TNFαm2 with different doses were added into 1x105/ml Jurkat H2/9855 cell suspensions respectively. After 24hrs,48 hrs and 72 hrs,the GFP in samples were determined by flow cytometry. The results showed that the increase of GFP expression level is along with the extended time of treatment with XE-TNFαm2,and it is depended on the dosage of XE-TNFαm2. This result indicated that XE-TNFαm2 is able to stimulate latent HIV to re-propagate in Jurkat H2/9855 cells.Thus,the host cell were became to be novel infected cells. On the other aspect, our previous study indicated that one of XE-TNFαm2 functions is to kill the cells infected by HIV/SIV. Accordingly, when the novel re-propagating HIVs start to pullulate, their gp120 must be appeared on the surface of host cells. Then,gp120 must be bound by XE in XE-TNFαm2, and latter’s killing signal must be transduced into cells.In that case, these host cells must be killed by XE-TNFαm2. Thus, the death of host cells leads to stop the propagation of un-maturated HIVs. Then, such kind of HIV without infection ability must be eliminated together with died host cells before that the re-propagated HIVs maturated to break host cells and to release out from cells.